Sanjiv Patel, Relay Therapeutics CEO
December 11, 2024 11:00 AM EST
R&D

Re­lay Ther­a­peu­tics plans piv­otal tri­al in sec­ond-line breast can­cer for 2025

Katherine Lewin

News Reporter

Re­lay Ther­a­peu­tics’ stock $RLAY rose about 6% on Wednes­day morn­ing af­ter it re­leased pos­i­tive in­ter­im da­ta for its PI3Kα in­hibitor in breast can­cer.

In the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Blue­bird bio to sell to in­vest­ment funds af­ter strug­gling to make mon­ey from gene ther­a­pies

FDA says Ozem­pic, We­govy short­age is over

Eli Lil­ly stock­piles $548M of oral weight loss drug ahead of launch

Pfiz­er ends roll­out of Be­qvez, putting an­oth­er dent in he­mo­phil­ia gene ther­a­py field

Nvidia-backed Achi­ra de­buts, blend­ing AI and physics to mod­el mol­e­cules

sponsored

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

A service from the Financial Times